COVID-19: From Pandemic to Common Respiratory Infection
Since the SARS-CoV-2 virus first emerged in 2019, its circulation has changed and shifted from a pandemic to seasonal circulation. This coupled with the re-emergence other seasonal pathogens—such as influenza and respiratory syncytial virus (RSV)—makes determining the correct infecting pathogen all the more vital for patient care. Several respiratory pathogens have similar symptoms, so the availability and accuracy of the right type of tests to deliver actionable results must be a priority.
Our tests provide information that may result in:
- Improved patient outcomes
- Decreased morbidity
- Decreased contamination risk
- Improved antibiotic stewardship (decrease in the use and duration of antibiotics)
- Reduced in unnecessary or ancillary testing
- Reduced in hospital admissions
- Reduced in length of stay
- Reduced in hospital-acquired infections
COVID-19 / SARS-CoV-2 - Our Diagnostic Offer
A Comprehensive Diagnostic Approach
COVID-19 patient management requires healthcare professionals to be alert to the patient’s needs throughout the entire patient journey. bioMérieux offers a comprehensive range of diagnostic tools to support COVID-19 patient care, from primary diagnosis and testing to discharge.
Disclaimer: Please consult your local bioMérieux representative for more information on our AMS, Sepsis, and Total Service Solutions.
Because patients with suspected COVID-19 present with an array of symptoms that can be caused by other infections and diseases, it is critical that the initial diagnoses are completed with tests that have the necessary high quality, validation, and regulatory market approvals. This ensures patient, clinician, and lab professional confidence. bioMérieux offers tests that identify SARS-CoV-2 as well as other respiratory bugs that cause symptoms similar to those of COVID-19.
BIOFIRE® FILMARRAY® TORCH
Easier testing. Faster results.
With integrated sample preparation, amplification, detection, and analysis, the BIOFIRE TORCH uses multiplex PCR technology to simultaneously test for a comprehensive grouping of targets in ~45 minutes to ~1 hour.
BIOFIRE® Respiratory 2.1 (RP 2.1) Panel
1 Test. 22 Targets. ~45 Minutes.
The BIOFIRE RP2.1 uses the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results may enable better-informed diagnosis and treatment of patients.
BIOFIRE® SPOTFIRE® System
This Changes Everything.
The SPOTFIRE System is a small, scalable, multiplex PCR platform designed to bring laboratory-grade diagnostic results to the decentralized point-of-care clinical setting.
BIOFIRE® SPOTFIRE® Respiratory Panels
Comprehensive Onsite PCR Results in ~15 Minutes.
Point-of-care respiratory testing solutions with SPOTFIRE Respiratory Panels offering rapid syndromic PCR tests for a range of common pathogens.
Diagnosing the correct respiratory causative pathogen is critical, but understanding the severity of the disease is equally as important. bioMérieux offers tests that indicate infection severity to support informed decision-making and patient care.
VIDAS® B•R•A•H•M•S PCT™
Important Biomarker for Improved Patient Management
PCT is a biomarker that provides information that may aid in the decision-making on antimicrobial therapy for lower respiratory tract infections.
VIDAS® D-DIMER EXCLUSION™ II
Safe Exclusion of Venous Thromboembolism
VIDAS® D-Dimer Exclusion™ II is a highly-sensitive automated D-Dimer assay. Used in conjunction with assessment of clinical pretest probability, it allows safe exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE) in both low and intermediate suspected outpatient risk groups in just 20 minutes.
VIDAS® NEPHROCHECK®
Know Earlier. Intervene Sooner. Avoid AKI.
VIDAS® NEPHROCHECK measures urinary TIMP-2 & IGFBP-7, specific urinary biomarkers for early risk assessment of moderate to severe Acute Kidney Injury (AKI). The VIDAS® NEPHROCHECK assay is intended to be used in conjunction with clinical evaluation as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) in acutely ill patients.
VIDAS® 3
Trusted. Robust. Innovative.
With its advanced immunoassay technology and optimized testing protocols, the fully automated VIDAS® 3 benchtop immunoanalyzer empowers your lab with confidence, offering the precise results you need, when you need them.
Often, patients with COVID-19 will develop secondary infections that need to be both addressed and managed. bioMérieux offers a variety of tests to determine if patients are suffering from additional bloodstream and/or respiratory infection to optimize patient management.
BIOFIRE® FILMARRAY® TORCH
Easier testing. Faster results.
With integrated sample preparation, amplification, detection, and analysis, the BIOFIRE TORCH uses multiplex PCR technology to simultaneously test for a comprehensive grouping of targets in ~45 minutes to ~1 hour.
BIOFIRE® Respiratory 2.1 (RP 2.1) Panel
1 Test. 22 Targets. ~45 Minutes.
The BIOFIRE RP2.1 uses the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results may enable better-informed diagnosis and treatment of patients.
BIOFIRE® FILMARRAY® Pneumonia (PN) Panel
1 Test. 33 Targets. ~1 Hour.
Syndromic tests targeting a comprehensive menu of pathogens that cause pneumonia and other lower respiratory tract infections, as well as 7 genetic markers of antibiotic resistance.
BIOFIRE® Blood Culture Identification 2 Panel
1 Test. 43 Targets. ~1 Hour.
The BIOFIRE BCID2 Panel tests for 43 targets associated with bloodstream infections, including gram-negative bacteria, gram-positive bacteria, yeast, and 10 antimicrobial resistance genes – all with one test and with results available in about an hour from positive blood culture.
BACT/ALERT® 3D
Accurate Blood Culture Results
BACT/ALERT® 3D brings flexible and modular automated detection systems for any size laboratory that needs to meet blood culture guidelines efficiently, economically, and effectively.
PREVI® COLOR GRAM
A Market-Leading Automated Gram Stainer Offering Confidence in Results
Gram staining is a key step in your microbiology workflow, and PREVI® COLOR GRAM is the system to streamline it and provide timely staining results for impactful decisions.
VITEK® MS PRIME
New-Generation Mass Spectrometry Microbial Identification System
A benchtop high-throughput automated identification system with a robust database that facilitates fast and confident microbial identification.
VITEK® 2
Fully integrated Identification and Antimicrobial Susceptibility Testing
Automated system for routine antimicrobial susceptibility built to enable efficient workflow and fast AST results. Its fully integrated ID/AST approach is designed to rapidly and confidently guide patient therapy.
CHROMID®
Chromogenic Media for Organism Isolation and Identification
Innovative and extensive range of chromogenic media for the simultaneous culture and identification of microorganisms in clinical specimens.
If a bacterial co-infection or secondary bacterial infection is realized with a COVID-19 patient, then it is necessary for antimicrobial treatment selection and monitoring to take place. As a leader in ID/AST, bioMérieux offers trusted and innovative products that provide hospitals and laboratories with solutions that support informed treatment decision-making.
VIDAS® B•R•A•H•M•S PCT™
Important Biomarker for Improved Patient Management
Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).
VITEK® 2
Fully integrated Identification and Antimicrobial Susceptibility Testing
Automated system for routine antimicrobial susceptibility built to enable efficient workflow and fast AST results. Its fully integrated ID/AST approach is designed to rapidly and confidently guide patient therapy.
ETEST®
Antibiotic Susceptibility Testing Reagent Strips to Determine On-Scale MICs
ETEST complements the VITEK® 2 automated system platform by offering a flexible and precise minimum inhibitory concentration (MIC) solution to test additional antibiotics.
BIOMÉRIEUX EPISEQ®
Next Generation Sequencing (NGS) Data Analysis Platform
Provides easy-to-use applications for clinical microbiologists: clinical pathogen outbreak management, microbiome profiling, and SARS-CoV-2 genomics variants identification.
BIOFIRE® Syndromic Trends
Turn BIOFIRE® System Results into Smart Pathogen Trending
Creating a global surveillance network that displays BIOFIRE® Panel test results from participating laboratories and hospitals around the world, BIOFIRE TREND allows users to explore epidemiology insights and better understand site-specific and regional pathogen trends and seasonality.
VILINK®
Optimize Instrument UPTIME to Improve Laboratory Productivity
A secure solution offering remote access, proactive maintenance, and remote updates. VILINK, solves software and instrument issues, and supports your systems to enable laboratory productivity and efficiency.
BIOMÉRIEUX EPISEQ®
Next Generation Sequencing (NGS) Data Analysis Platform
Provides easy-to-use applications for clinical microbiologists: clinical pathogen outbreak management, microbiome profiling, and SARS-CoV-2 genomics variants identification.
BIOMÉRIEUX LAB CONSULTANCY
Microbiology Expertise and Consultancy to Optimize Lab Performance
Our team will empower your lab by optimizing processes to help you make the most out of your innovative technology.
Useful Resources on COVID-19 / SARS-CoV-2
Contact Us About Our COVID-19 / SARS-CoV-2 Solutions
Contact Us
References
1WHO Director-General’s opening remarks at the media briefing on COVID19 -March 2020